Premium
Nonglycosidic Agonists of Invariant NKT Cells for Use as Vaccine Adjuvants
Author(s) -
Reddy B. Gopal,
Silk Jonathan D.,
Salio Mariolina,
Balamurugan Rengarajan,
Shepherd Dawn,
Ritter Gerd,
Cerundolo Vincenzo,
Schmidt Richard R.
Publication year - 2009
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.200800354
Subject(s) - cd1d , natural killer t cell , priming (agriculture) , antigen , vaccination , immunology , immunotherapy , immune system , biology , t cell , botany , germination
Based on the crystal structures of human α‐GalCer–CD1d and i NKT–α‐GalCer–CD1d complexes, nonglycosidic analogues of α‐GalCer were synthesized. They activate i NKT cells resulting in dendritic cell maturation and the priming of antigen‐specific T and B cells. Therefore, they are attractive adjuvants in vaccination strategies for cancer and infectious diseases.